Geode Capital Management LLC increased its position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 24.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 554,957 shares of the biopharmaceutical company’s stock after purchasing an additional 109,012 shares during the quarter. Geode Capital Management LLC owned 0.88% of Dicerna Pharmaceuticals worth $5,932,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. lifted its stake in Dicerna Pharmaceuticals by 46.0% in the fourth quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock valued at $46,300,000 after buying an additional 1,364,155 shares during the last quarter. Vanguard Group Inc lifted its stake in Dicerna Pharmaceuticals by 40.7% in the third quarter. Vanguard Group Inc now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after buying an additional 573,197 shares during the last quarter. Vanguard Group Inc. lifted its stake in Dicerna Pharmaceuticals by 40.7% in the third quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after buying an additional 573,197 shares during the last quarter. Federated Investors Inc. PA lifted its stake in Dicerna Pharmaceuticals by 61,484.1% in the third quarter. Federated Investors Inc. PA now owns 252,495 shares of the biopharmaceutical company’s stock valued at $3,853,000 after buying an additional 252,085 shares during the last quarter. Finally, Emory University bought a new stake in Dicerna Pharmaceuticals in the fourth quarter valued at $1,844,000. Hedge funds and other institutional investors own 85.29% of the company’s stock.

In related news, insider James B. Weissman sold 15,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the sale, the insider now directly owns 39,480 shares in the company, valued at $592,200. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 19.85% of the stock is owned by insiders.

Shares of NASDAQ DRNA opened at $13.79 on Friday. Dicerna Pharmaceuticals Inc has a fifty-two week low of $9.31 and a fifty-two week high of $17.98. The stock has a market cap of $941.37 million, a P/E ratio of -11.49 and a beta of 2.42.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 53.27%. The company had revenue of $1.54 million for the quarter, compared to the consensus estimate of $8.38 million. On average, research analysts predict that Dicerna Pharmaceuticals Inc will post -0.99 EPS for the current year.

A number of research firms have issued reports on DRNA. Zacks Investment Research cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Cowen began coverage on Dicerna Pharmaceuticals in a research note on Tuesday, February 26th. They issued an “outperform” rating on the stock. Finally, B. Riley raised their target price on Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $21.78.

COPYRIGHT VIOLATION NOTICE: “Dicerna Pharmaceuticals Inc (DRNA) Shares Bought by Geode Capital Management LLC” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://theolympiareport.com/2019/04/20/dicerna-pharmaceuticals-inc-drna-shares-bought-by-geode-capital-management-llc.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.